

DALE B. SCHENK et al.
Application No.: 09/724,551
Page 3

PATENT

REMARKS

Applicants have amended claims 47 and 67, and added new claims 69-71. Support for the amendment of claims 47 and 67, and new claims 69-71 is found throughout the specification, e.g., page 18, lines 28-29. Thus, the amended and new claims raise no new matter.

Applicant elects the following species:

Species 1B: humanized antibodies;

Species 2B: monoclonal antibodies;

Species 3A: IgG1; and,


Species 4D: antibodies that bind to an epitope within residues 3-7 of A β .

Claims 47 and 67-71 read on humanized antibodies (species 1B), monoclonal antibodies (species 2B), and IgG1 (species 3A). Claims 47, 67-68, and 71 read on antibodies that bind to an epitope within residues 3-7 of A β (species 4D).

Applicants maintain the traverse of the requirement to elect a species of Group 4.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-326-2400.

Respectfully submitted,


Rosemarie L. Celli
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
RLC:lah
PA 3289740 v1